Clinical Trial

Artificial Intelligence and Gestacional Diabetes

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Artificial intelligence (AI) technology can assist medical teams in remote monitoring and continuing education of women with gestational diabetes (GDM), potentially improving adherence to interventions and impacting outcomes. An AI remote monitoring model called "monitoring model for women with GDM using pharmacological therapy," created by the ChamouDr technical team, will be analyzed focusing on disease education, glycemic control monitoring, and therapeutic interventions. Women diagnosed with GDM are invited to participate in the study and sign a free and informed consent form. The AI tool is installed on the pregnant woman's cell phone, who receives instructions to collect capillary blood glucose 6 times a day according to the protocol, at home, and report the results via WhatsApp to the study tool. Algorithm generated by the AI model based on self monitoring of blood glucose (SMBG) informs about diabetes control in the last week. The dashboard is accessible via a web browser, and signals: in green and red for patients with satisfactory and unsatisfactory control, respectively. Thus, the AI model optimizes the team's time in analyzing and treating patients appropriately in a simple, cost-effective, and accessible way.
Trial Details
NCT Number NCT07345143
Lead Sponsor JOSE FERNANDO VILELA-MARTIN
Conditions Gestational Diabetes, Macrosomia, Fetal
Enrollment 100 participants
Start Date 2024-06-01
Primary Completion 2026-12-20 (estimated)
Study Completion 2027-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-15